Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Xinhua Silk Road: Quanzhou builds global connections through living heritage
BEIJING, Dec. 17, 2025 /PRNewswire/ -- Once hailed by Marco Polo as a "great eastern port" teeming with merchants and goods, Quanzhou, a world heritage city in southeast China's Fujian Province, today continues to captivate visitors with its living...
MMTEC, Inc. Announces Receipt of Nasdaq Decision Regarding Minimum Bid Price Deficiency
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), a China-based technology company that provides access to the U.S. financial markets, today announced that on December 9, 2025, the Company...
China Premiere of 'Avatar: Fire and Ash' Highlight of 7th HIIFF
HAIKOU, China, Dec. 10, 2025 /PRNewswire/ -- A report from Hainan International Media Center: On the evening of Dec. 9th, the 7th Hainan Island International Film Festival (HIIFF) concluded. This thrilling event was held just prior to the imminent...
NaaS Technology Inc. Regains Compliance with Nasdaq Minimum Market Value of Listed Securities Requirement
BEIJING, Dec. 10, 2025 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, today announced that on December 9, 2025, it received written notice from the Listing...
Culture and tourism sectors thrive in Xiamen
BEIJING, Dec. 10, 2025 /PRNewswire/ -- A report from China Daily: China Daily publishes an eight-page spread on Wednesday to showcase Xiamen’s high-quality development during 2021-25. Driven by its commitment to high-level opening-up, Xiamen, Fujian...
Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of...
Keio Plaza Hotel Tokyo Wins Grand Prize at Eco Mark Award 2025
- Keio Plaza Hotel Recognized for Its Company-wide Sustainability Promotion, Food Waste Reduction and Installation of Clothing Collection Boxes - TOKYO, Dec. 9, 2025 /PRNewswire/ -- Keio Plaza Hotel Co., Ltd. received the highest award, the Grand...
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer...